Loxo announces positive interim data from dose escalation trial in RET-altered cancers

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Loxo Oncology Inc. announced interim clinical data from the LOXO-292 global phase I LOXO-292 Investigated to Block RET-altered Tumors dose escalation trial.

To access this subscriber-only content please log in or renew you subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login